

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q92967

Noboru YAMAZAKI, et al.

Appln. No.: 10/566,566

Group Art Unit: Not Yet Assigned

Confirmation No.: 6156

Examiner: Not Yet Assigned

Filed: February 1, 2006

For: TARGET-DIRECTED AND ENTERIC ABSORPTION-CONTROLLED  
LIPOSOME HAVING SUGAR CHAIN AND CANCER REMEDY AND  
DIAGNOSTIC CONTAINING THE SAME

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy an International Search Report in a counterpart application citing such documents.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Renita S. Rathinam  
Registration No. 53,502

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: August 21, 2006

Substitute for Form 1449 A & B/PTO  <b><u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u></b>  <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/566,566
				Confirmation Number	6156
				Filing Date	February 1, 2006
				First Named Inventor	Noboru YAMAZAKI
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	Q92967

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US 2003/0143267	A1	07/31/2003	Noboru YAMAZAKI

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		JP	2001-81044	A	03/27/2001	TOKAI UNIVERSITY	Yes

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		International Search Report dated November 9, 2004.	
		HONG, Ruey-Long et al., "Direct Comparison of Liposomal Doxorubicin With or Without Polyethylene Glycol Coating in C-26 Tumor-bearing Mice: Is Surface Coating With Polyethylene Glycol Beneficial?" Clinical Cancer Research, 1999, pages 3645 to 3652, Vol. 5.	
		KAMPS, Jan A.A.M. et al., "Massive Targeting of Liposomes, Surface-Modified With Anionized Albumins, to Hepatic Endothelial Cells", Proc. Natl. Acad. Sci. 1997, pages 11681 to 11685, Vol. 94, USA.	
		KOLE, Labanyamoy et al., "Synergistic Effect of Interferon-γ and Mannosylated Liposome-incorporated Doxorubicin in the Therapy of Experimental Visceral Leishmaniasis", 1999, pages 811 to 820, Vol. 180.	
		TAKEUCHI, Hirofumi et al., "Passive Targeting of Doxorubicin with Polymer Coated Liposomes in Tumor Bearing Rat", Biol. Pharm. Bull., 2001, pages 795 to 799, Vol. 24.	
		YAMAZAKI, Noboru et al., "Preparation and Characterization of Neoglycoprotein-liposome Conjugates: A Promising Approach to Developing Drug Delivery Materials Applying Sugar Chain Ligands", Trends in Glycoscience and Glycotechnology, 2001, pages 319 to 329, Vol., 13, No., .	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.